Hemab Therapeutics Doses First Volunteer in Phase 1 HMB-003 Study

08:43 AM EDT, 09/17/2026 (MT Newswires) -- Hemab Therapeutics (COAG) dosed the first healthy volunteer in a phase 1 trial evaluating investigational HMB-003 for heavy menstrual bleeding, the company said Thursday. HMB-003 showed greater activity than tranexamic acid in preclinical models, while a single subcutaneous dose in minipigs provided about one week of sustained antifibrinolytic activity, the company said. The randomized, placebo-controlled trial is assessing HMB-003's safety, tolerability, pharmacokinetics and pharmacodynamics in healthy adults. Hemab expects to report results by mid-2027 that will inform development plans for heavy menstrual bleeding and other bleeding conditions, it added.